title: Harnessing impaired energy metabolism in cancer cell: small molecule- mediated ways to regulate tumorigenesis.
abstract: Altered cellular metabolism is a hallmark of tumorigenesis. Described first in 1924 by Otto Warburg, a cancer cell undergoes complete metabolic reprogramming to attain nutrient self-sufficiency for proliferation and survival. Interplay between diverse signalling cascades confers this metabolic advantage. In this review we focus on signalling molecules that regulate this altered metabolic paradigm in a cancer cell with emphasis on small molecule mediated intervention for attenuation of growth and progression of tumor.
authors: Chemical Biology Programme, Institute of Life Sciences, Hyderabad, University of Hyderabad Campus, Gachibowli, Hyderabad,
  500032, India
authors: K Shroff
authors: KS
authors: Govardhan
authors: Chemical Biology Programme, Institute of Life Sciences, Hyderabad, University of Hyderabad Campus, Gachibowli, Hyderabad,
  500032, India
authors: Kuna
authors: K
authors: Ramyasri
authors: Chemical Biology Programme, Institute of Life Sciences, Hyderabad, University of Hyderabad Campus, Gachibowli, Hyderabad,
  500032, India
authors: Dirisipam
authors: D
authors: Kethora
authors: Chemical Biology Programme, Institute of Life Sciences, Hyderabad, University of Hyderabad Campus, Gachibowli, Hyderabad,
  500032, India
authors: Yalagala
authors: Y
authors: Ravishekar
authors: Chemical Biology Programme, Institute of Life Sciences, Hyderabad, University of Hyderabad Campus, Gachibowli, Hyderabad,
  500032, India
authors: Mitra
authors: M
authors: Prasenjit
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000378:metabolism; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005947:Glucose / Q000378:metabolism; D006019:Glycolysis / Q000187:drug effects; D006593:Hexokinase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D051379:Mice; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D051058:Oncogene Protein v-akt / Q000235:genetics / Q000378:metabolism; D010085:Oxidative Phosphorylation / Q000187:drug effects; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D054852:Small Molecule Libraries / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D016271:Proto-Oncogene Proteins c-myc; D054852:Small Molecule Libraries; D006593:Hexokinase; D051058:Oncogene Protein v-akt; D058570:TOR Serine-Threonine Kinases; D005947:Glucose